报价延迟最少15分钟:2026/04/15 09:36 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.05 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
--/-0.73
|
|
企业价值
191.35M
|
| 资产负债 |
|
每股账面净值
-7.06
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
114.20M
|
|
每股收益
2.59
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets. |
